No 10Y consistency score yet for revenue — the year-earlier revenue was zero, negative or too small a base to compare against in 20 of the 40 quarters in the window, leaving 20 comparable quarters; at least 28 are needed.
Valuation vs own 10Y history: P/S N/A · No P/S — trailing revenue unavailable or non-positive.
Annualized revenue (TTM) · by quarter, last 40
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
The latest delayed quote for Enveric Biosciences, Inc. (ENVB) stock was $1.51 as of Oct 5, 2026, 4:00 PM EDT, up 2.03% from the previous close.
Enveric Biosciences, Inc. is a pharmaceutical firm focused on advancing diverse cannabinoid-based medications, primarily for use in cancer care.
Biotechnology · Cambridge, MA
Next Earnings Date
Nov 12, 2026
37 days away
EPS Estimate
N/A
Revenue Est.
N/A
Last Quarter Results
EPS
$-0.76
vs Estimate
N/A
Revenue
$0.00
vs Estimate
N/A
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1ENVB | $6.76M | $1.51 | +2.03% | N/A | N/A | N/A | N/A |
| 2ACON | $6.74M | $2.34 | -1.68% | -68.01% | N/A | N/A | vs ENVB |
| 3BOLT | $6.72M | $3.50 | +1.42% | -33.96% | -57.61% | N/A | vs ENVB |
| 4CODX | $6.88M | $1.10 | +1.85% | -90.34% | -66.53% | N/A | vs ENVB |
| 5KALA | $7.01M | $0.36 | -5.84% | -99.52% | -85.73% | N/A | vs ENVB |
| 6CURX | $7.03M | $4.96 | +5.08% | -68.03% | N/A | N/A | vs ENVB |
forward FY estimate
N/A
Consensus Rating
No analyst recommendations available
Average Price Target
N/A
Low
N/A
Current
$1.51
High
N/A
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Dec 2026 | $-1575.00 | $-1575.00 | $-1575.00 | 1 |
| Quarter ending Mar 2027 | $-1260.00 | $-1260.00 | $-1260.00 | 1 |
| Quarter ending Jun 2027 | $-1440.00 | $-1440.00 | $-1440.00 | 1 |
| Quarter ending Sep 2027 | $-720.00 | $-720.00 | $-720.00 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-315.00 | $-315.00 | $-315.00 | 1 |
| FY 2027 | $-111.60 | $-111.60 | $-111.60 | 1 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Dec 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Mar 2027 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Jun 2027 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Sep 2027 | $0.00 | $0.00 | $0.00 | 0 |
Annual
| Period | Low |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $10.00M | $10.00M | $10.00M | 1 |
| FY 2027 | $15.00M | $15.00M | $15.00M | 1 |
